Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.
Also called NCT02899455
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 146 participants
- Registry
-
NCT02899455
-
- Other papers using this trial's data
- A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02899455. Randomized; double masking; primary purpose treatment. Start 2014-07 (registry gives no type); primary completion 2016-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia
- Condition
- Hypertension
- Condition
- Hyperlipidemia
- Intervention (Drug)
- HGP0904
- Intervention (Drug)
- HGP0608
- Intervention (Drug)
- HGP0816
- Intervention (Drug)
- HGP0904 Placebo
- Intervention (Drug)
- HGP0816 Placebo
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct02899455- Content hash
c7c4120bd6f9df56b64f655d9bf91ba210d061f1a6afd684a062794777b3c0bf